News
-
-
-
-
PRESS RELEASE
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Horus Pharma partners with Formycon for Eylea biosimilar commercialization in Europe under Baiama brand. Agreement includes upfront payments and royalties for Klinge. Aflibercept treats nAMD -
-
-
-
PRESS RELEASE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Formycon AG analysis, maintaining BUY rating with increased target price of €49. Company aims for 2025 revenue of €55-65m and improved financial position after new corporate bond issuance -
-
PRESS RELEASE
Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
Formycon AG to discuss 2025 half-year results in conference call and attend international investor conferences in the 3rd quarter of 2025. Details and registration info provided